Replies to post #91836 on Magic

[Billybob_TX]

$AIKI news: NEW YORK , Feb. 22, 2021 /PRNewswire/ --  AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced an update on its broad spectrum anti-viral platform compounds with the potential to treat influenza, COVID-19, Ebola and other viral infections.  The initial two lead compounds, which target the SKI complex in humans, have been optimized through the use of computer assisted learning, through two rounds of chemical modifications to achieve drug-like properties required to move the compounds into animal testing.  In addition, a third lead compound has been identified and will be subjected to optimization. These new compounds are currently being tested against Influenza virus with testing on SARS-CoV-2 in the near future.  Subsequently, the top analogs from each series of lead compounds will be selected for tests of their anti-viral effects in a SARS-CoV-2 mouse model.